Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension - GlobeNewswire
globenewswire.comSubmitted by globenewswire9432 in business
AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses......